GlobeNewswire Inc.··NaCardiff Oncology to Present Onvansertib Phase 2 Data at ASCO 2026
Cardiff Oncology will present updated Phase 2 data for onvansertib in RAS-mutated colorectal cancer at ASCO 2026 in June.
CRDFcolorectal cancerphase 2 trial
bevacizumab
3 articlesGlobeNewswire Inc.··NaGlobeNewswire Inc.··Researchandmarkets.ComAvastin Market Poised for 45% Growth Through 2030 as Biosimilars Expand Access
Avastin market projected to grow from $7.82B in 2025 to $11.27B by 2030 at 7.5% CAGR, driven by cancer prevalence and biosimilar expansion.
RHHBYcolorectal cancercancer treatment
Benzinga··Not SpecifiedOutlook Therapeutics Launches Capital Raise Through Public Stock Offering
Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.
OTLKwarrantspublic offering